Clinical trials: HSCT, open to volunteers
Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells.
- Conditions
- Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
- Trial name
- NCT00920972
- Testing
- Treatment Plan 1: Stratum 1, Treatment Plan 2: Strata 2, 3, or 4, GVHD Regimen A: UCB Recipients
- Where
- 28 sites in United States, Canada
- Volunteers
- 220 people
- Sponsor
- Washington University School of Medicine
Acute Leukemia, Severe Aplastic Anemia
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion.
- Conditions
- Acute Leukemia, Severe Aplastic Anemia, Non-hodgkin Lymphoma, Hodgkin Lymphoma
- Trial name
- NCT04099966
- Testing
- alpha beta depletion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mitchell Cairo
Acute Leukemia, MDS
Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
A research investigation into the efficacy of digital Polymerase Chain Reaction (dPCR) for monitoring measurable residual disease (MRD) during allogeneic hematopoietic stem cell transplantation, with a focus on predicting relapse…
- Conditions
- Acute Leukemia, MDS, MDS/MPN, CML
- Trial name
- NCT06211166
- Testing
- Digital PCR, Quantitative PCR, MFC
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University People's Hospital
Immunocompromised Patients
Immunogenicity and Safety of Two Respiratory Syncytial Virus Vaccine Strategies in Lung and Allogeneic Haematopoietic Stem Cell Transplant Recipients.
Respiratory syncytial virus (RSV) is a major cause of acute respiratory infections (ARIs), which occur in seasonal outbreaks. Among the adult population, immunocompromised individuals, particularly lung transplant recipients and…
- Trial name
- RSVAxID (NCT07863401)
- Testing
- RSVpreF3-AS01, RSVpreF3
- Where
- 16 sites in France
- Volunteers
- 400 people
- Sponsor
- Hospices Civils de Lyon
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), Oxygen Deficiency
Impact of Closed PBSC Collection With Reduced Gas-Phase Oxygen Exposure on Graft Quality and Early Engraftment in Allo-HSCT
This study aims to establish a closed PBSC collection procedure with reduced gas-phase oxygen exposure and to verify its impact on graft functional quality and clinical engraftment efficiency.
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), Oxygen Deficiency, Graft Function
- Trial name
- NCT07904234
- Testing
- Closed PBSC collection with reduced gas-phase oxygen exposure
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies.
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
- Trial name
- NCT07216443
- Testing
- Orca-T
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- Orca Biosystems, Inc.
Oral Mucositis
Efficacy of High-Level Laser Therapy in Managing Oral Mucositis Among Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation
The goal of this clinical trial is to learn if high-level laser therapy can manage oral mucositis in pediatric patients undergoing hematopoietic bone marrow transplantation.
- Trial name
- NCT07436650
- Testing
- high power laser therapy, Basic oral care
- Where
- Egypt
- Volunteers
- 14 people
- Sponsor
- Ain Shams University
Acute Leukemia
A Retrospective Study on the Relationship Between Donor Leukocyte Telomere Length and Prognosis of Acute Leukemia Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation
This post hoc analysis included patients with acute leukemia who underwent allo-HSCT at the First Affiliated Hospital of Zhejiang University School of Medicine and Ruijin Hospital Shanghai Jiaotong University School of Medicine.
- Trial name
- NCT06076226
- Testing
- No intervention, observation study
- Where
- China
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Zhejiang University
Acute Myeloid Leukemia
A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation
A Trial to Evaluate the Safety and Efficacy of iNK in the Treatment of Subjects for Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation.
- Trial name
- NCT06441084
- Testing
- NCR300 injection
- Volunteers
- 15 people
- Sponsor
- Nuwacell Biotechnologies Co., Ltd.
Bronchiolitis Obliterans Syndrome (BOS), HSCT
Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients
Allogeneic hematopoietic stem cell transplantation (HSCT) is burdened with a high morbidity and mortality rates. Graft versus host disease (GVHD) is the clinical manifestation of an immune conflict.
- Conditions
- Bronchiolitis Obliterans Syndrome (BOS), HSCT, Bronchial Disease
- Trial name
- IMMUNO-BOS (NCT07771855)
- Testing
- Tezepelumab
- Where
- 6 sites in France
- Volunteers
- 36 people
- Sponsor
- Hopital Foch
Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
The study is a Phase II clinical trial. Patients will receive intensity-modulated total marrow irradiation (TMI) at a dose of 9 Gray (Gy) with standard myeloablative fludarabine intravenous (IV) and targeted busulfan (FluBu4)…
- Conditions
- Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory, Chronic Myeloid Leukemia - Accelerated Phase, Myelodysplastic Syndromes
- Trial name
- BMT-13 (NCT06802315)
- Testing
- Intensity modulated total marrow irradiation, Cyclophosphamide (CTX), Fludarabine (Fludara)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Illinois Chicago
Myeloid Malignancy, Acute Myeloid Leukemia
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
The goal of this interventional clinical trial is to determine if low doses of gentle chemotherapy after bone marrow transplant may prevent relapse and promote an increase in survival and decrease in side effects in participants…
- Trial name
- NCT06129734
- Testing
- Venetoclax, Decitabine
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Benjamin Tomlinson
Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
This trial aims to find the MTD of Venetoclax when added to Fludarabin, Amsacrine and Ara-C + Treosulfan and to evaluate whether the addition of Venetoclax to sequential conditioning with FLAMSA + Treosulfan is safe for…
- Conditions
- Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT05807932
- Testing
- Venetoclax, Amsacrine, Ara-C
- Where
- 6 sites in Germany
- Volunteers
- 38 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
HSCT, Hematologic Cancer
The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignance Patients With Extramedullary Infiltrating
Application of Stereotactic Body Radiotherapy (SBRT) Bridging to Allogeneic Hematopoietic Stem Cell Transplantation in Adult Hematological Malignance Patients with Extramedullary Lesions.
- Trial name
- NCT07456189
- Testing
- Stereotactic body radiotherapy (SBRT)
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Haematopoietic Stem Cell Transplantation
Precision Medicine for Stem Cell Transplantation
A study of patients undergoing haematopoietic stem cell transplantation, a procedure in which patients are infused with stem cells from a donor, resulting in a new immune system that eliminates cancer or replaces diseased bone…
- Trial name
- PM-SCT (NCT05567289)
- Testing
- Blood sample collection, Bone marrow aspirate
- Where
- 3 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- University of Manchester
Myeloid Leukemia, Acute
Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry
Evaluation of variation of mineral density and bone microarchitecture after allogeneic HSCTs transplant in hematologic malignancies. Comparison with the general population.
- Trial name
- REMODALLO (NCT05161026)
- Testing
- Bone osteodensitometry
- Where
- 4 sites in France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Caen
B-cell Acute Lymphoblastic Leukemia
Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the main method potentially curing adult B-ALL, but the high treatment-related mortality (NRM) affects overall survival (OS).
- Trial name
- NCT06507514
- Testing
- blinatumomab and auto-HSCT "sandwich " strategy
- Where
- China
- Volunteers
- 4 people
- Sponsor
- The First Affiliated Hospital of Soochow University
EBV-T/NK LPD
Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host Disease
To investigate whether the addition of recombinant humanized anti-CD25 monoclonal antibody to the conventional EBV-T/NK LPD conditioning regimen can prevent acute and chronic GVHD after transplantation, improve the severity of…
- Trial name
- NCT07029958
- Testing
- recombinant humanized anti-CD25 monoclonal antibody
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Children's Hospital
Hematopoietic and Lymphatic System Neoplasm
Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
This phase I trial studies how well biomarker-guided ruxolitinib works for the prevention of chronic graft versus host disease (GVHD) in patients that have undergone allogeneic hematopoietic cell transplant (HCT).
- Trial name
- NCT07025538
- Testing
- Best Practice, Biomarker Analysis, Biospecimen Collection
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- City of Hope Medical Center
Bone Marrow Transplant (BMT)
HPC Offered for PRESERVE Expansion
Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons.
- Trial name
- HOPE (NCT07145411)
- Testing
- Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Ossium Health, Inc.